Evolus Inc (EOLS) Q4 2025 Earnings Call Transcript

Why It Matters

The results demonstrate Evolus’s ability to grow in a shrinking procedural market, positioning it for profitable expansion and resilience against upcoming competitive launches.

Key Takeaways

• Q4 revenue $90.3M, 14% growth YoY.
• Full-year revenue $297.2M, 12% growth, six years double‑digit.
• Jeuveau holds 14% US market share, growing.
• Evolisse faces 15% tariff, possible extra 5%.
• 2026 guidance: $327‑337M revenue, low‑single‑digit EBITDA margin.

Pulse Analysis

Evolus’s earnings underscore a rare combination of top‑line momentum and disciplined cost management in a market where U.S. injectable volumes have contracted for the first time in 25 years. The company’s flagship neurotoxin, Jeuveau, not only retained a 14% share of a declining market but also expanded its footprint, while the filler line Evolisse, despite a 15% tariff, added meaningful revenue and is poised for broader adoption pending FDA approval of Evolisse Sculpt. This resilience is bolstered by a stable gross margin around 66‑67% and a cash position of $53.8 million, complemented by a new revolving credit facility and untapped debt capacity, providing ample liquidity for inventory and growth initiatives.

Strategic initiatives played a pivotal role in the quarter’s performance. Evolus introduced a portfolio‑growth rebate to incentivize multi‑product purchasing, reinforcing cross‑selling opportunities across its clinic network. The company also amplified its educational outreach, delivering hands‑on training to over 14,000 clinicians and launching immersive flagship events at its headquarters, which deepen practitioner loyalty and drive product adoption. Internationally, revenue grew to 8% of total sales, with the U.K. approaching double‑digit toxin market share, signaling a successful expansion beyond the United States and setting the stage for the upcoming European launch of Esteem.

Looking ahead, Evolus projects 2026 revenue between $327 million and $337 million, targeting low‑to‑mid single‑digit adjusted EBITDA margins and full‑year profitability. The guidance accounts for anticipated competitive pressure from AbbVie and Galderma, as well as potential tariff escalations on Evolisse. Nevertheless, the company’s long‑term ambition of $450‑$500 million in revenue and 13‑15% adjusted EBITDA margins by 2028 remains anchored by its cash‑pay business model, expanding product portfolio, and continued focus on operational leverage. Stakeholders should watch the rollout of Evolisse Sculpt and the European Esteem launch, which could accelerate growth and further diversify earnings streams.